Systemic biomarkers for the dynamic assessment of tumor burden and treatment efficacy in high grade gliomas
AssigneesTrustees of Dartmouth College, Mary Hitchcock Memorial Hospital, for itself and on behalf of Dartmouth-Hitchcock Clinic
InventorArti Gaur
Life of this patent
Estimating the term…
Abstract
Embodiments of the present disclosure pertain to methods of assessing glioma in a subject by (1) receiving a plurality of measured biomarker levels of the subject; and (2) assessing glioma in the subject based on the measured biomarker levels by at least correlating differentially expressed levels of the measured biomarkers to at least one of (a) diagnosis of glioma, (b) progression of glioma, (c) treatment outcome, and/or (d) tumor burden. The methods of the present disclosure also include a step of (3) making a treatment decision based on the assessment. Additional embodiments of the present disclosure pertain to systems for assessing glioma in a subject.
Claims38
A method of assessing glioma in a subject, said method comprising:
- receiving a plurality of measured biomarker levels of the subject, wherein the plurality of measured biomarker levels comprise one or more measured microRNA levels and one or more measured protein levels,
- wherein the one or more measured microRNA levels comprise one or more measured levels of hu-mir-103a-3p, hu-mir-146a-5p, hu-mir-2-1-5p, hu-mir-221-3p, hu-mir-26a-5p, hu-mir-26b-5p, hu-mir-30d-5p, hu-mir-126-3p, hu-mir-126-5p, hu-mir-142-3p, hu-mir-223-3p, hu-mir-196b-5p, hu-mir-151a-3p, or combinations thereof, and
- wherein the one or more measured protein levels comprise one or more measured levels of CCL11, CCL2, CCL22, EGF, FGF-2, CXCL1, G-CSF, GM-CSF, IFN-α2, IL-6, IL-10, IL-12p40, IL-12p70, IL-15, IL-1Rα, IL-1α, TNFα, PDGF-AA, VEGF, or combinations thereof;
- and
- assessing glioma in the subject based on the measured biomarker levels, wherein the assessing comprises correlating differentially expressed levels of the measured biomarkers to at least one of diagnosis of glioma, progression of glioma, treatment outcome, tumor burden, or combinations thereof.
4-6. (canceled)
14-15. (canceled)
(canceled)
26-27. (canceled)
A system for assessing glioma in a subject, wherein the system comprises a computing device, and wherein the computing device comprises:
- programming instructions for receiving a plurality of measured biomarker levels of the subject, wherein the plurality of measured biomarker levels comprise one or more measured microRNA levels and one or more measured protein levels,
- wherein the one or more measured microRNA levels comprise one or more measured levels of hu-mir-103a-3p, hu-mir-146a-5p, hu-mir-2-1-5p, hu-mir-221-3p, hu-mir-26a-5p, hu-mir-26b-5p, hu-mir-30d-5p, hu-mir-126-3p, hu-mir-126-5p, hu-mir-142-3p, hu-mir-223-3p, hu-mir-196b-5p, hu-mir-151a-3p, or combinations thereof, and
- wherein the one or more measured protein levels comprise one or more measured levels of CCL11, CCL2, CCL22, EGF, FGF-2, CXCL1, G-CSF, GM-CSF, IFN-α2, IL-6, IL-10, IL-12p40, IL-12p70, IL-15, IL-1Rα, IL-1α, TNFα, PDGF-AA, VEGF, or combinations thereof;
- and
- programming instructions for assessing glioma in the subject based on the measured biomarker levels, wherein the assessing comprises correlating differentially expressed levels of the measured biomarkers to at least one of diagnosis of glioma, progression of glioma, treatment outcome, tumor burden, or combinations thereof.
34-36. (canceled)
44-45. (canceled)
Dependencies are inferred from the claim text.